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Abstract
Background: Resistance amongst the commensal flora is a serious threat because a very highly populated ecosystem
like the gut, may at a later stage, be a source of extra intestinal infections, resistant strains may spread to other host or
transfer genetic resistance element to other members of micro-biota including pathogens. This study was carried out
to assess fecal colonization by carbapenemase producing Enterobacteriaceae (CPE) and associated risk factors among
100 patients admitted to intensive care unit (ICU). The phenotypic and molecular characterizations of CPE were also
included.
Results: Colonization with CPE was observed in 6.6 % (8/122) controls. Among ICU patients, fecal carriage of CPE was
significantly higher on day 4 (D4) (22 %) as compared to day 1 (D1) (11 %) (p value 0.002). The carbapenemase genes
detected included OXA- 48, 181, KPC and NDM-1 with NDM-1 being the predominant carbapenemase in both ICU D1
and D4. Among the 50 CPE isolates, 8 (16 %) were susceptible to meropenem and imipenem (Minimum inhibitory
concentration; MIC ≤ 1 mg/L) and all were susceptible to colistin (MIC range 0.125 - 1 mg/L) and tigecycline (MIC range
0.06- 1.5 mg/L).
The risk factors associated with CPE carriage were duration of ICU stay, use of ventilator and aminoglycosides.
Conclusions: Prior colonization with CPE could result in their influx and spread in ICU, challenging infection control
measures. Exposure to ICU further increases risk of colonization with diverse carbapenemase-producing Enterobacteriaceae.
Gut colonization with these strains may be a source of endogenous infection and horizontal transfer of these
genes in future.
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Background
Antibiotic resistance is observed in both pathogenic bac-
teria and normal commensal flora [1]. Current strategies to
monitor antibiotic resistance mainly examine pathogenic
organisms and only periodic cross-sectional evaluations of
resistance are undertaken for commensal flora [2]. Mem-
bers of family Enterobacteriaceae heavily colonize human
gut and are the most frequent cause of bacterial infections
in patients of all ages [3]. Their ubiquity and frequent
acquisition of mobile genetic elements means that their
human hosts are regularly exposed to new strains with
novel genetic repertoires including antibiotic resistance
through food, water, and from other animate and inanimate
sources in the community [3]. Resistance amongst the
commensal flora is a serious threat because a very highly
populated ecosystem like the gut, may at a later stage, be a
source of extra intestinal infections, resistant strains may
spread to other host or transfer genetic resistance element
to other members of micro-biota including pathogens [4].
Extended spectrum β-lactamase (ESBL) producing
Enterobacteriaceae are widely disseminated in India and
carbapenems are drug of choice for infections due to
ESBL producers [5, 6].
As gastrointestinal tract may serve as a reservoir for
carbapenem resistant Enterobacteriaceae (CRE), resulting
in cross transmission in health care settings, active surveil-
lance among high risk patients is necessary for prevention
and control of their dissemination in acute care facilities
[7]. In most surveillance studies perianal and rectal cul-
tures were generally found to be most reliable for screen-
ing colonization with resistant Enterobacteriaceae [8].
Several studies have been conducted to assess the risk fac-
tors associated with colonization and infection caused by
ESBL producing Enterobacteriaceae [9, 10]. There is pau-
city of data regarding fecal carriage of CRE.
The predominant mechanism of carbapenem resistance
among Enterobacteriaceae is through acquisition of diverse
carbapenemases belonging to class A, B and D. Recent re-
ports suggest that NDM-1 (Class B, metallo-β-lactamase) is
widely distributed among Enterobacteriaceae in the envir-
onmental samples and key enteric pathogens in India [6].
This study was undertaken to assess fecal colonization
with carbapenemase producing Enterobacteriaceae (CPE)
and associated risk factors among patients admitted to in-
tensive care unit (ICU). Antibiotic susceptibility profile and
molecular characteristics of these isolates were also studied.
Methods
Specimen collection
The study was conducted in a 10 bedded ICU from
September 2011 and September 2012. Patients requir-
ing intensive care or ventilator support were admitted
directly to ICU from the emergency department or oper-
ation theatre and included patients of acute poisoning,
neurological or cardiovascular emergency, acute respira-
tory failure and patients undergoing emergency and elect-
ive surgery. Patients transferred to the ICU from other
wards and/or hospitals were excluded. Two rectal swabs
were collected from all enrolled patients (n = 100), one
each on day 1 (D1) and day 4 (D4) of ICU admission and
transported in nylon flocked system in Amies liquid trans-
port medium. Patients, in whom D4 sample could not be
collected, were excluded from the study. To study risk
factors for colonization; demographic data, clinical history,
current antibiotic therapy, including carbapenems, in-
vasive procedures and co-morbid conditions were re-
corded through chart review in a predesigned proforma
(Additional file 1). Controls included, stool samples
from 122 non-hospitalized patients attending the out-
patient department for routine health checkup. This
study was approved by the Institute Ethics Committee,
V.M.M.C & Safdarjung Hospital (S.NO. VMMC/SJH/
Ethics/SEP-11/29).
Isolation and identification
Approximately 0.5gm of stool or rectal swab was emulsi-
fied in 0.5 ml of sterile 0.85 % saline. Screening of CRE
was done on in-house prepared media by four different
methods and included: (i) overnight selective enrichment
in 5 ml tryptic soy broth with a 10 μg ertapenem disk
followed by plating onto MacConkey agar (CDC proto-
col) [11], (ii) direct plating onto MacConkey agar sup-
plemented with imipenem at 1 mg/L (MacI), (iii) direct
plating onto MacConkey agar supplemented with cefo-
taxime at 1 mg/L (MacC ESBL), (iv) MacConkey agar
with standard imipenem, meropenem and ertapenem
Disk (10 μg Disk), applied at the 4-, 8-, and 12-o’clock
positions (MacD). Evaluation of bacterial growth was
made after 18 to 24 h of incubation at 37 °C in ambient
air. All morphologically distinct colonies were sub cul-
tured on standard MacConkey agar plate and isolates were
identified by conventional biochemical tests [12]. The
media used in the study had been previously validated for
isolation of CRE harbouring carbapenemase genes (KPC,
IMP, VIM, NDM-1, OXA-48 and OXA-181).
Susceptibility testing and phenotypic detection of
β-lactamases
Antibiotic susceptibility was performed by disk diffusion as
per clinical and laboratory standards institute (CLSI) 2012
guidelines [13] for ampicillin (10 μg), trimethoprim-
sulfamethoxazole (1.25/23.75 μg), piperacillin (100 μg),
ceftazidime (30 μg), cefotaxime (30 μg) cefoxitin (30 μg),
piperacillin-tazobactam (100/10 μg), cefoperazone-sulbactam
(75/30 μg), netilmicin (30 μg), amikacin (30 μg), gentamycin
(10 μg), nalidixic acid (30 μg), ciprofloxacin (5 μg), tetracyc-
line (30 μg). All Enterobacteriaceae were screened for carba-
penem resistance using ertapenem (10 μg), meropenem
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(10 μg), imipenem (10 μg) disk and results were interpreted
as per CLSI 2012 guidelines. All isolates with ertapenem
zone diameter <22 mm were subjected to minimum in-
hibitory concentration (MIC) for ertapenem, merope-
nem, imipenem, colistin and tigecycline using E test
(bioMérieux, France). Isolates with ertapenem MIC >
0.5 mg/L were defined as CRE. Resistant and susceptible
to tigecycline were defined as MIC 2 mg/L and ≤1 mg/L
respectably (European committee on antimicrobial sus-
ceptibility testing; EUCAST 2011).
All CRE were screened for β-lactamases by phenotypic
test and PCR. For phenotypic test commercially available
KPC, MBL and ESBL/AmpC Screen kit (Rosco Diagnos-
tica, Denmark) containing meropenem and cefotaxime
alone and with various β-lactamase inhibitors (boronic acid,
dipicolinic acid, clavulanic acid, cloxacillin and clavulanic
acid + cloxacillin) were used. Zone diameters were re-
corded. Tests were interpreted as per manufacture
instruction.
PCR for β-lactamases among CRE
DNA was isolated by phenol chloroform method as per
Sambrook et al. [14]. PCR was performed for ESBL
(SHV, TEM and CTX-M), AmpC (MOX, FOX, DHA,
CIT, ACC, EBC) and Class A (KPC1 and 2), Class B
(NDM-1, IMP, VIM) and class D (OXA- 48 and OXA-181)
carbapenemases. PCR product were electrophoresed on
1.5 % agarose gel along with a 100 bp DNA ladder (as a
molecular wt marker) and visualized using a UV transillu-
minator. For TEM [5], SHV [5], CTX-M [15], AmpC [16],
NDM-1 [5], IMP [5], VIM [5], KPC [5] and OXA-181 [17]
previously designed primers were used. For OXA–48,
primer (self-deigned) used was FP (5′-GCGTGTATTAGC
CTTATC-3′) and RP (5′-CGCGGTTCGGTAGTGTGT
TT-3′), which amplifies a 760 bp product. Cycling con-
ditions were: 95 °C for 5 min; 30 cycles of 95 °C for
30s, 60 °C for 30s and 72 °C for 60s; and 72 °C for
5 min. Selected amplicons were sequenced. All primers
were procured from Integrated DNATechnologies (IDT).
CRE growing on selective media and positive for any
carbapenemase gene were defined as carbapenemase pro-
ducing Enterobacteriaceae (CPE). Non-CPE were defined
as all CRE isolates growing on selective media and nega-
tive for any carbapenemase gene.
Controls used for antibiotic susceptibility, phenotypic
test and PCR included ESBL-positive Klebsiella pneumo-
niae ATCC 700603, ESBL-negative Escherichia coli ATCC
25922, KPC-positive Klebsiella pneumoniae ATCC
BAA-1705, KPC-negative Klebsiella pneumoniae ATCC
BAA-1706. For IMP, VIM, NDM-1, OXA-48 and OXA-
181 in house strains confirmed by sequencing were
used as controls.
Figure 1 shows the flowchart of steps to study
colonization with CPE.
Statistical analysis
Antibiotic resistance data was analyzed using
WHONET 5.6. χ2 test was used for comparison of
prevalence fecal carriage of CPE in ICU patients D1
vs D4 and ICU vs controls. Statistical significance was
taken as p value <0.05.
Risk factors for colonization with CPE among ICU
patients were compared using χ2 or Fisher exact
test, as appropriate. All p values were two tailed. p
value <0.05 was considered statistically significant.
Adjusted odds ratios and 95 % confidence intervals
(CIs) were computed for the significant factors. Vari-
ables that were present in more than 10 % of ICU
patients with CPE colonization with p value <0.05
were entered into backward stepwise logistic regres-
sion models in multivariate analysis using SPSS ver-
sion 20.0 (SPSS, Chicago, IL)
Results
Isolation and characteristics of CRE and CPE from
fecal samples are summarized in Tables 1 & 2. A
total of 322 fecal samples were screened which in-
cluded a single sample from 122 controls and 200
samples from 100 ICU patients, collected on D1 and
D4. A total of 444 morphologically distinct Entero-
bacteriaceae were isolated from 89 (72.9 %) controls,
63 (63 %) and 58 (58 %) ICU patients on D1 and D4
respectively. Although 4 media were used for screen-
ing of CRE & CPE, duplicate isolates were excluded.
Ertapenem MIC > 0.5 mg/L was observed among 91/
444 (20.5 %) Enterobacteriaceae and were defined as
CRE. Isolation of CRE was significantly higher among
ICU patients on D4 (35/100, 35 %) compared to con-
trols (14/122, 11.5 %) (p value 0.0001) and ICU-D1
(20/100, 20 %) (p value 0.02) (Table 1).
Carbapenemase genes were detected among 50/91
CRE isolates and were defined as CPE. Colonization with
CPE was observed among 6.6 % (8/122) controls as
compared to 11 % (11/100) ICU patients on D1 (p value
0.3). Colonization increased to 22 % (22/100) on D4 of
ICU stay (p value 0.001). Among 7 ICU patients CPE
was present on both ICU-D1 and ICU-D4 (Table 1).
Carbapenemases were detected in diverse genera,
Escherichia coli (39/50) was the predominant species in
both ICU and control patients followed by Proteus sp.,
Klebsiella sp. and Enterobacter sp.
Among 91 CRE isolates synergy between merope-
nem with dipicolinic acid was observed among 36
CRE isolates and was predictive of presence of
metallo-β-lactamases. Disks containing this combin-
ation generated zone diameters of at least 5 mm lar-
ger (mean 12 mm larger, range 5–19 mm) than those
containing meropenem alone (10 μg); However the
zones with meropenem plus dipicolinic acid were
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≥27 mm in all but 3 isolates indicating coexistence of
other non-metallo-β lactamases in the latter strains.
Synergy with boronic acid, predictive of KPC or class A
enzymes, was observed in 2 isolates. Synergy with clavula-
nic acid and or cloxacillin was observed in 36 CRE isolates
and predicted presence of ESBL, AmpC or co-producers.
17 CRE isolates were negative for all phenotypic tests sug-
gesting a presence of a class D carbapenemases or ESBL
and/or AmpC with altered permeability due to efflux or
changes in outer membrane porins. There was a good cor-
relation between phenotypic test and PCR for carbapene-
mase genes. Isolates with OXA-48 and OXA-181
genotype showed no synergy with dipicolinic acid and bo-
ronic acid.
Amongst the controls, NDM-1 was the only carbapene-
mase gene detected. Amongst ICU patients carbapenemase
genes were diverse (OXA-48, OXA-181 and KPC) with
predominance of NDM-1. Diversity and number of coexist-
ing carbapenemase genes increased with ICU stay (Table 2).
NDM-1 co-existed with OXA-48, OXA-181 and KPC
genotype co-existed with OXA-181. Among 50 CPE, 45
(90 %) were positive for ESBL genes, commonest being
CTX-M 1. The predominant AmpC genes among CPE iso-
lates were DHA, MOX and CIT. Details of these genes are
shown in Table 2.
Scatter plots (Fig. 2) showing MIC of meropenem and
imipenem among Non-CPE (CRE isolates negative for
carbapenemase genes, n = 41) and CPE (n = 50) were
Fig. 1 The flowchart of steps to study colonization with Carbapenemase producing Enterobacteriaceae (CPE)
Table 1 Colonization pattern of CRE and CPE among controls and ICU patients
Controls (%) ICU
D1 (%) D4 (%)
Total no. of patients screened 122 100 100
Total no. of patients with growth of Enterobacteriaceae 89 (72.9) 63 (63) 58 (58)
No of patients colonized with CRE 14 (11.5) 20 (20) 35 (35)**
No of patients colonized with CPE 8 (6.6) 11 (11) 22 (22)**
CRE carbapenem resistant Enterobacteriaceae, CPE carbapenemase producing Enterobacteriaceae, Non CPE non carbapenemase producing Enterobacteriaceae, D1
Day 1, D4 Day 4. **p value significant compared to ICU D1 (<0.05) and controls (<0.05)
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constructed. Majority of the Non-CPE isolates were sus-
ceptible to meropenem (0.047 mg/L - 1 mg/L) and imi-
penem (0.25 mg/L - 1 mg/L). However 5 isolates showed
high level resistance to both imipenem and meropenem
(MIC ≥ 32 mg/L) but were negative both by phenotypic
test and PCR for carbapenemase genes, 1 isolate was
susceptible to meropenem (MIC 0.125 mg/L) and resist-
ant to imipenem (MIC 1.5 mg/L). Among CPE, 36 iso-
lates showed high level resistance to both imipenem and
meropenem. For one isolate meropenem and imipenem
MIC were 1.5 mg/L and 3 mg/L respectively. 8 CPE
isolates were susceptible to both imipenem (MIC range
0.38 mg/L – 1 mg/L) and meropenem (MIC range
0.38 mg/L – 0.75 mg/L), 5 isolates were susceptible to
meropenem (MIC range 0.38 mg/L – 1 mg/L) but resist-
ant to imipenem (MIC range 1.5 mg/L - 4 mg/L).
Susceptibility patterns of CPE and MIC of colistin and
tigecycline
Amongst 50 CPE, 27 and 13 isolates were resistant to 6
(amikacin, gentamicin, ampicillin, cefoxitin, ceftazidime,
ciprofloxacin, ertapenem, imipenem) and 5 (ampicillin,
cefoxitin, ceftazidime, ciprofloxacin, ertapenem, imipe-
nem) classes of antimicrobial agents respectively.
MIC distributions to colistin and tigecycline among
CPE and Non-CPE are shown in Fig. 3. All isolates were
susceptible to colistin (MIC range 0.125 mg/L to 1 mg/L)
and there was no significant difference (p value ≥0.05) in
MIC50 and MIC90 among CPE and Non-CPE.
Table 2 Phenotypic and molecular characteristics of CRE and






Characteristics of CRE (n = 91) 20 31 40
1. Species distribution pattern
Escherichia coli 16 28 30
Klebsiella sp. 2 3 9
Proteus sp. 2 0 0
Enterobacter sp. 0 0 1
2. MIC range (mg/L)
Ertapenem 0.75-64 0.75-64 0.75-64
Imipenem 0.25-64 0.25-64 0.25-64
Meropenem 0.064-64 0.047-64 0.064-64
3. Phenotypic characterization
MBL 10 11 15
KPC 0 0 2
Non MBL/KPC Carbapenemase 0 3 9
Only ESBL and/or AmpC 10 15 11
No β lactamases class 0 2 3
Characteristics of CPE isolates (n = 50) 10 14 26
1. Species distribution pattern
Escherichia coli 6* 14¥ 19$
Klebsiella sp. 2* 0 6
Proteus sp. 2* 0 0
Enterobacter sp. 0 0 1#
2. MIC range (mg/L)
Ertapenem 64-64 3-64 2-64
Imipenem 64-64 0.38-64 0.38-64
Meropenem 64-64 0.5-64 0.38-64
3. Distribution of β- lactamases
TEM 4 10 14
SHV 1 4








Characteristics of NON-CPE isolates
(n = 41)
10 17 14
1. Species distribution pattern
Escherichia coli 10 14 11
Table 2 Phenotypic and molecular characteristics of CRE and
CPE isolates from fecal samples (Continued)
Klebsiella sp. 3 3
2. MIC range (mg/L)
Ertapenem 0.75-8 0.75-64 0.75-64
Imipenem 0.25-2 0.25-64 0.25-64
Meropenem 0.064-0.75 0.047-64 0.064-64
3. Distribution of β- lactamases
TEM 5 9 9




No enzyme detected 2 3 2
CRE carbapenem resistant Enterobacteriaceae, CPE carbapenemase producing
Enterobacteriaceae, Non CPE non carbapenemase producing
Enterobacteriaceae, D1 Day 1, D4 Day 4. *All NDM -1 (n = 10); ¥NDM-1 (n = 11),
OXA-48(n = 1), OXA-48 + NDM-1(n = 1), OXA-181(n = 1); $NDM-1(n = 12),
OXA-48 + 181(n= 4), OXA-48(n= 1), OXA-48 +NDM-1(n= 1), OXA-48 + 181 +NDM-1
(n= 1); NDM-1(n= 3), KPC (n= 1), OXA-48,181(n= 1), KPC +OXA-181(n= 1);
#OXA-181(n= 1)
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Using EUCAST 2011 breakpoint, the MIC range of
tigecycline for CPE and Non-CPE isolates was 0.064 mg/L
to 1.5 mg/L and 0.064 mg/L to 2 mg/L respectively. Al-
though MIC50 and MIC90 did not differ, two Non-CPE
isolates showed MIC at breakpoint i.e. 2 mg/L.
Risk factors associated with CPE colonization in ICU
patients (Table 3)
At the time of sampling, 59/100 (59 %) of ICU patients
were under antibiotic therapy with 17 % receiving a com-
bination of agents. The most frequently used antibiotics
were third generation cephalosporin (n = 45) followed by
carbapenems (n = 14), aminoglycosides (n = 11), fluroqino-
lones (n = 9), augmentin (n = 5). Invasive procedures
among ICU patients included use of peripheral catheter
(n = 83), ventilator (n = 61), naso-gastric tube (n = 43),
central venous line (n = 35), oxygen mask (n = 21). Co-
morbid conditions observed were chronic lung disease
(n = 20), surgical procedure (n = 15) and neoplasia (n = 7).
In Univariate logistic regression model, use of carbapen-
ems (p value 0.02), aminoglycosides (p value 0.02), ventila-
tor (p value 0.01) and surgical procedures (p value 0.048)
were associated with a risk of CPE colonization. A multi-
variate logistic regression model was constructed to adjust
Fig. 2 Scatter plot showing MIC of meropenem (MEM) Vs Imipenem (IPM). Note: Among Carbapenemase producing Enterobacteriaceae (CPE), 8
isolates with MEM and IPM MIC ≤1 mg/L (sensitive) were positive for carbapenemase gene. Among Non-carbapenemase producing Enterobacteriaceae
(Non-CPE), 5 isolates with MEM and IPM MIC≥ 16 mg/L (resistant) were negative for carbapenemase gene
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for confounding variables. Use of aminoglycosides and
ventilator were the only variables independently associated
with CPE colonization. ICU stay was a significant risk fac-
tor as colonization was significantly higher on D4 of ICU
stay as compared to ICU-D1 (p value 0.002, OR 8.633).
Discussion
Very few studies have reported fecal carriage by CPE in
non-outbreak conditions. A study from Pakistan [7] has
reported fecal carriage of CPE (NDM-1) among 64/200
(18.5 %) hospitalized and out patients at military hospital
Rawalpindi. As there are limited reports of gut colonization
with CPE among ICU patients, this prospective study was
undertaken to evaluate gut colonization with CPE and
associated risk factors. Patients without prior history of
hospitalization and admitted to the ICU for intensive
care or ventilator support were included in the study.
Colonization by CRE and CPE were studied at D1 and
D4. Patients colonized with Enterobacteriaceae de-
creased from 63/100 on ICU-D1 to 58/100 on ICU-D4.
This is explained by subsequent colonization with Aci-
netobacter sp., Pseudomonas sp., other nil-fermenters
and Candida sp. by D4 of ICU stay (data not shown).
The CPE colonization rate of 11 % on D1 was similar
to colonization rates among non-hospitalized controls
(6.6 %, p value >0.05). In view of our exclusion criteria
these findings suggest acquisition of these isolates out-
side the hospital. This is further supported by NDM-1
being the predominant carbapenemase gene in both
groups. NDM-1 producing Enterobacteriaceae may be
disseminated in community and is supported by a re-
cent study [6] which estimated a prevalence of 100 mil-
lion carriers of NDM harboring bacteria in India alone.
Unrecognized influx of NDM-1 producing Enterobacte-
riaceae in ICU may hinder infection control measures.
It is thus critical to screen patients harbouring NDM-1
producing Enterobacteriaceae as they may be a source
of infection acquired either endogenously or through hori-
zontal transfer. In this study among 26 ICU patients colo-
nized with CPE (DI and/or D4), 12 % developed sepsis
due to NDM-1 producing Enterobacteriaceae. Interest-
ingly although Acinetobacter spp. was the predominant
cause of sepsis in ICU during the study period, we were
also able to demonstrate NDM-1 gene among carbapenem
Fig. 3 MIC of colistin and tigecycline amongst CPE and Non-CPE
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resistant Acinetobacter spp. isolates suggesting the possi-
bility of interspecies transmission (data not shown).
Patients colonized with CRE and CPE increased sig-
nificantly from 20 % & 11 % on D1 to 35 % & 22 % re-
spectively on D4 (p value <0.05). We could not study
the transmission pathway of CPE among ICU patients
due to non-availability of funds and resources. It is
speculated that various mechanism could have contrib-
uted to the spread of CPE isolates from D1 to D4 of
ICU stay. As carbapenemase gene co-exist with virulence
and other antibiotic resistance gene on transmissible ele-
ments like plasmids, they can spread by horizontal transfer
in diverse species in a highly populated ecosystem like gut.
Secondly patients in ICU are exposed to the resistant flora,
have co-morbid conditions and are subjected to invasive
procedures, and hence these patients are at risk of acquir-
ing MDR strain like VRE, ESBL, and CPE due to cross
transmission resulting from breech of infection control
practices. NDM-1 gene was the predominant carbapene-
mase gene observed among non-hospitalized patients and
ICU patients on D1 of admission. Interestingly the diversity
of genes increased on D4 of ICU stay and included NDM-
1, OXA-48,181 and KPC. Moreover on D4 of ICU stay,
18 % (9/50) of the CPE isolates were found to have more
than 1 carbapenemase gene. Similarly diversity of genera
with carbapenemase genes was also observed. On D1, E.coli
was the only Enterobacteriaceae with NDM-1 gene. On D4,
NDM-1 gene was also isolated from Klebsiella sp., Entero-
bacter sp. and was found to co-exist with KPC and OXA
genes suggesting horizontal transfer of plasmids and resist-
ance genes among isolates. However the possibility of hori-
zontal transfer of strains between patients via hands of
health care workers cannot be ruled out.
There is paucity of data regarding risk factors predis-
posing to gut colonization with CPE. In this study, using
multivariate analysis, ICU stays of >72 h, ventilator-use
and treatment with aminoglycoside were independently
associated with risk of CPE colonization. As mentioned
above use of invasive procedure and ICU stay increase
chances of transmission of multidrug resistant organism.
Specific antibiotics and antibiotic classes have frequently
been implicated as risk factors for colonisation or infec-
tion with CPE, and these include all the carbapenems,
cephalosporins, fluoroquinolones, aminoglycosides and
β-lactam/β-lactamase inhibitors [18]. The plasmids that
confer such resistance frequently carry additional resist-
ance determinants that confer cross-resistance to most
other antibiotic classes. Consequently, prior use of any
antibiotic may select for a carbapenemase-producing
bacteria. Increased use of aminoglycoside in absence of
Table 3 Univariate analysis of risk factors for fecal colonization by CPE among ICU patients
RISK Factors Total Patients N = 100 P value Odds
Ratio
Confidence
IntervalNo of patients Patients with CPE (n = 26) (%) Patients without CPE (n = 74) (%)
Sex (Male) 58 17 (65.3) 41 (55.4) 0.37 1.52 0.600 3.849
Antibiotics use
Carbapenems 14 7 (26.9) 7 (9.5) 0.027 3.528 1.1 11.304
Cephalosporins 45 13 (50) 32 (43.2) 0.55 1.313 0.536 3.125
Aminoglycosides 11 6 (23.1) 5 (6.8) 0.032 4.14 1.143 14.994
Augmentin 5 1 (3.8) 4 (5.4) 0.75 0.700 0.075 6.565
Fluoroqinolones 9 3 (11.5) 6 (8.1) 0.59 1.478 0.342 6.393
Interventions used
Central venous line 35 12 (46.2) 23 (31.1) 0.16 1.901 0.761 4.744
Ventilator 61 21 (80.8) 40 (54.1) 0.01 3.570 1.216 10.483
Peripheral catheter 83 22 (84.6) 61 (82.4) 0.79 1.172 0.345 3.978
Naso-gastric tube 43 15 (57.7) 28 (37.8) 0.07 2.240 0.903 5.559
Oxygen Mask 21 6 (23.1) 15 (20.3) 0.7 1.180 0.403 3.454
Co-morbid conditions
Surgery 15 7 (26.9) 8 (10.8) 0.048 3.039 0.976 9.461
Chronic lung disease 20 2 (7.7) 18 (24.3) 0.06 0.259 0.056 1.206
Neoplasia 7 1 (3.8) 6 (8.1) 0.4 0.453 0.052 3.955
Multivariate analysis
Ventilator 0.027 0.291 0.097 0.871
Aminoglycosides 0.046 0.257 0.068 0.975
CPE carbapenemase producing Enterobacteriaceae
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carbapenem pressure can select resistance to carbapen-
ems as was observed in present study. Similar to our
findings, a study from Pakistan also reported that dur-
ation of hospitalization (irrespective of ICU) was statisti-
cally associated with a higher likelihood of carriage of
CPE (p value < 0.05). However; this study reported co-
amoxyclave as a risk factor of CPE colonization with
NDM [19].
In present study, using 4 different in-house prepared
selective media, carbapenemase gene was detected in 50
non duplicate isolates of Escherichia coli, Klebsiella sp.,
Proteus sp. and Enterobacter sp. The data on comparison
on the performance of various media is not shown.
There was an excellent correlation among the phenotypic
test and PCR results for identification of CPE isolates.
Diagnostic disks using meropenem ± boronic acid and
meropenem ± dipicolinic acid were 100 % predictive of
production of class A and class B enzymes respectively.
Forty one CRE were negative for various Carbapenemase
genes screened (Non-CPE) and 5 of these isolates showed
high level resistance to both meropenem and imipenem. As
these isolates were positive for ESBL and/or AmpC, possi-
bility of other coexisting mechanisms contributing to carba-
penemase resistance either due to a novel carbapenemase
gene or alteration in permeability due to over expression of
efflux pump or alteration in outer membrane porins needs
to be investigated.
Multidrug Resistance was common with resistance to 5
and 6 classes of antibiotics observed among CPE isolates
from controls and ICU respectively, leaving few thera-
peutic options for treatment and includes colistin and
tigecycline. All 50 isolates of CPE were susceptible for co-
listin and tigecycline with MIC range 0.125 mg/L -1 mg/L
and 0.064 mg/L -1.5 mg/L respectively.
There are a few limitations of the study. Firstly, the data
on co morbidities among controls which included non-
hospitalized patients presenting at the out-patient depart-
ment for routine stool examination as a part of health
check was not available and hence the actual risk of health-
care associated colonization cannot be ruled out. Secondly,
due to lack of resources we could not study the transmis-
sion pathway of CPE among ICU patients. However there
is enough evidence of horizontal transfer of CPE among
patients and diverse bacterial isolates.
Conclusion
To conclude gut colonization by CPE among ICU pa-
tients on D1 is alarming, unrecognized influx of CPE in
ICU may hinder infection control measure. NDM-1 car-
bapenemase was most common gene Exposure to ICU
further increases the risk of colonization with diverse
carbapenemase genes. Isolation of CPE with MIC to
meropenem and imipenem within susceptible range
(MIC ≤ 1 mg/L) further challenges their detection in
surveillance cultures. Various other mechanisms may
also contribute to carbapenem resistance. Therefore fur-
ther characterization should be performed on all sus-
pected isolates with slightest decrease in susceptibility to
carbapenems especially ertapenem. Therapeutic options
for treating carbapenem resistant Enterobacteriaceae in-
fections include colistin and tigecycline.
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